Omeros (OMER) News Today $8.10 -1.73 (-17.60%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$8.11 +0.01 (+0.11%) As of 10/17/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Why Is Omeros Dropping Today?Toggle Visibility of Why Is Omeros Dropping Today?Omeros Corporation (OMER) — Shares moved sharply after a licensing deal and follow‑on analyst and media coverage. The near‑term rally was driven by a large Novo Nordisk agreement, while volatility and a subsequent gap down reflect profit‑taking and heavy intraday volume. Positive Sentiment: Novo Nordisk licensed Omeros’ MASP‑3 inhibitor zaltenibart in a deal worth up to $2.1 billion (≈$340M upfront plus milestones). The transaction brings immediate non‑dilutive cash, validates Omeros’ MASP‑3 program, and creates material upside via milestones/royalties if development succeeds. Novo Nordisk snaps up Omeros’ rare disease asset for up to $2.1bn Positive Sentiment: HC Wainwright raised near‑ and long‑term EPS forecasts and reiterated a Buy rating with a $20 target, signaling analyst confidence that the company’s pipeline and partner deal materially improve Omeros’ path to profitability. This supports higher valuation expectations over the next several years. FY2025 Earnings Estimate for Omeros Issued By HC Wainwright Positive Sentiment: Omeros published peer‑reviewed data showing survival benefits with narsoplimab in TA‑TMA, strengthening the clinical and commercial story for its MASP‑2 program and adding credibility to the company’s complement‑pathway franchise. Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Neutral Sentiment: Wide media and analyst coverage (Seeking Alpha, Zacks, Blockonomi, Motley Fool) amplified investor attention and trading interest after the deal; coverage drove higher volume but is descriptive rather than new fundamental data. Omeros: Novo Nordisk's Licensing Deal Sends Shares Soaring, Makes Bull Case Negative Sentiment: After an initial surge, shares later gapped down amid heavy trading and profit‑taking; MarketBeat flagged the gap‑down and asked whether investors should sell — signaling short‑term volatility risk despite the deal. Traders should expect large intraday swings. Omeros (NASDAQ:OMER) Shares Gap Down - Should You Sell? Posted 1+ days agoAI Generated. May Contain Errors. OMER Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Omeros Corporation (NASDAQ:OMER) Receives Average Recommendation of "Moderate Buy" from Analysts1 hour ago | americanbankingnews.comOmeros Corporation (NASDAQ:OMER) Given Average Rating of "Moderate Buy" by Brokerages1 hour ago | marketbeat.comHC Wainwright Has Positive Outlook of Omeros FY2025 Earnings49 minutes ago | americanbankingnews.comOmeros (NASDAQ:OMER) Trading Down 13.7% - Time to Sell?October 18 at 12:45 PM | marketbeat.comOmeros' (OMER) Buy Rating Reiterated at D. Boral CapitalOctober 18 at 2:39 AM | americanbankingnews.comOmeros (NASDAQ:OMER) Price Target Raised to $20.00October 18 at 2:39 AM | americanbankingnews.comOmeros' (OMER) "Strong-Buy" Rating Reiterated at WBB SecuritiesOctober 18 at 2:39 AM | americanbankingnews.comOmeros: Novo Nordisk Deal Highlights MASP-3 Alternative Pathway TargetingOctober 17 at 4:51 PM | seekingalpha.comOmeros (NASDAQ:OMER) Shares Gap Down - Should You Sell?October 17 at 11:46 AM | marketbeat.comFY2025 Earnings Estimate for Omeros Issued By HC WainwrightOctober 17 at 6:07 AM | marketbeat.comPharmaceutical Stocks To Follow Now - October 15thOctober 16 at 3:23 PM | marketbeat.comNovo Nordisk snaps up Omeros’ rare disease asset for up to $2.1bnOctober 16 at 3:04 PM | finance.yahoo.comOmeros: Novo Nordisk's Licensing Deal Sends Shares Soaring, Makes Bull CaseOctober 16 at 10:11 AM | seekingalpha.comOmeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control GroupOctober 16 at 8:30 AM | businesswire.comA Deal With Novo Nordisk Sent This Stock 181% Higher Overnight. Is It a Buy Now?October 16 at 4:10 AM | fool.comHims & Hers, Salesforce, Omeros, United Airlines, And Sea Ltd: Why These 5 Stocks Are On Investors' Radars TodayOctober 15, 2025 | benzinga.comOmeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug DealOctober 15, 2025 | benzinga.comOmeros' (OMER) Hold Rating Reiterated at Needham & Company LLCOctober 15, 2025 | marketbeat.comOmeros (NASDAQ:OMER) Price Target Raised to $20.00 at HC WainwrightOctober 15, 2025 | marketbeat.comOmeros (NASDAQ:OMER) Earns "Strong-Buy" Rating from WBB SecuritiesOctober 15, 2025 | marketbeat.comOmeros (NASDAQ:OMER) Shares Gap Up - Here's WhyOctober 15, 2025 | marketbeat.comNovo Nordisk to Buy Blood Disease Drug From Omeros for Up to $2.1 BillionOctober 15, 2025 | wsj.comOmeros stock soars after $2.1 billion deal with Novo NordiskOctober 15, 2025 | za.investing.comNovo Nordisk and Omeros announce asset purchase and license agreement for Omeros’ clinical-stage MASP-3 inhibitor zaltenibart (OMS906)October 15, 2025 | markets.businessinsider.comOmeros Shares Soar On Sale of Blood Disease Drug to Novo NordiskOctober 15, 2025 | marketwatch.comD. Boral Capital Reiterates "Buy" Rating for Omeros (NASDAQ:OMER)October 15, 2025 | marketbeat.comNovo Nordisk to Pay Omeros Up to $2.1 Billion For Blood Disease DrugOctober 15, 2025 | wsj.comOmeros Signs Major Deal with Novo NordiskOctober 15, 2025 | tipranks.comNovo Nordisk signs up to $2.1 billion licensing deal with Omeros in rare disease pushOctober 15, 2025 | reuters.comNovo Nordisk and Omeros announce asset purchase and license agreement for Omeros' clinical-stage MASP-3 inhibitor zaltenibart (OMS906)October 15, 2025 | globenewswire.comOmeros (NASDAQ:OMER) Earns Sell (D-) Rating from Weiss RatingsOctober 10, 2025 | marketbeat.comOmeros (OMER) Receives a Buy from IntermonteOctober 1, 2025 | theglobeandmail.comOmeros Corporation Completes Promising Phase 2 Study on OMS906 for PNHOctober 1, 2025 | tipranks.comOmeros Corporation (NASDAQ:OMER) Receives Average Recommendation of "Moderate Buy" from BrokeragesSeptember 24, 2025 | marketbeat.comOmeros (NASDAQ:OMER) Stock Rating Upgraded by Wall Street ZenSeptember 20, 2025 | marketbeat.comAncora Advisors LLC Has $48,000 Position in Omeros Corporation $OMERSeptember 9, 2025 | marketbeat.comD. Boral Capital Reaffirms "Buy" Rating for Omeros (NASDAQ:OMER)September 5, 2025 | marketbeat.comNomura Holdings Inc. Trims Position in Omeros Corporation $OMERSeptember 4, 2025 | marketbeat.comPromising Clinical Data and Unique Mechanism of Narsoplimab Justify Buy RatingSeptember 3, 2025 | tipranks.comNuveen LLC Makes New $938,000 Investment in Omeros Corporation $OMERSeptember 3, 2025 | marketbeat.comOmeros Corporation: Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access ProgramSeptember 2, 2025 | finanznachrichten.deOmeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access ProgramSeptember 2, 2025 | businesswire.comWellington Management Group LLP Acquires New Stake in Omeros Corporation $OMERSeptember 2, 2025 | marketbeat.comOmeros Corporation (NASDAQ:OMER) Given Average Recommendation of "Moderate Buy" by BrokeragesSeptember 1, 2025 | marketbeat.comOmeros Corporation’s Positive Earnings Call Highlights ProgressAugust 31, 2025 | tipranks.comVanguard Group Inc. Has $26.61 Million Stock Position in Omeros Corporation $OMERAugust 31, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Has $87,000 Stock Position in Omeros Corporation $OMERAugust 23, 2025 | marketbeat.comFY2025 EPS Estimates for Omeros Raised by Cantor FitzgeraldAugust 22, 2025 | marketbeat.comOmeros: Deja Vu All Over Again (Rating Downgrade)August 20, 2025 | seekingalpha.comOmeros Corporation (OMER) Q2 2025 Earnings Call TranscriptAugust 19, 2025 | seekingalpha.com Get Omeros News Delivered to You Automatically Sign up to receive the latest news and ratings for OMER and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OMER Media Mentions By Week OMER Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OMER News Sentiment▼0.500.48▲Average Medical News Sentiment OMER News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OMER Articles This Week▼385▲OMER Articles Average Week Get the Latest News and Ratings for OMER and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Omeros and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies NKTR News PCRX News ASMB News CPIX News LLY News JNJ News ABBV News MRK News PFE News BMY News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OMER) was last updated on 10/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Omeros Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Omeros With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.